HC Wainwright Raises Price Targets for Kodiak and Mirum
HC Wainwright lifted Kodiak Sciences’ target to $126 from $96 and Mirum Pharmaceuticals’ target to $200 from $195 per share.
- published
- in the api
- on the website
- updated
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Dow Jones Newswires reported that HC Wainwright & Co. raised its price target for Kodiak Sciences to $126.00 per share from $96.00. Benzinga was cited as the source for the ratings action.
According to the Newsmetry API, HC Wainwright & Co. also increased its target for Mirum Pharmaceuticals to $200.00 per share from $195.00. The firm maintained its Buy rating on Mirum Pharmaceuticals. Benzinga was likewise listed as the source of the ratings action.
why it matters
The target-price changes show that analysts have revised their valuation of both biopharmaceutical companies. Keeping Mirum Pharmaceuticals at Buy means the recommendation itself was unchanged while the target was raised.
instruments
sources
- Kodiak Sciences Price Target Raised to $126.00/Share From $96.00 by HC Wainwright & Co. — Dow Jones Newswires, 12 October 2026 at 11:46 UTC
- Mirum Pharmaceuticals Price Target Raised to $200.00/Share From $195.00 by HC Wainwright & Co. — Newsmetry API, 12 October 2026 at 17:18 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗